EXOC5

Summary

EXOC5 (exocyst complex component 5, HGNC:10696) is a protein-coding gene on chromosome 14q22.3, encoding Exocyst complex component 5 (O00471). Component of the exocyst complex involved in the docking of exocytic vesicles with fusion sites on the plasma membrane. It is a selective cancer dependency (DepMap: 48.8% of cell lines).

The protein encoded by this gene is a component of the exocyst complex, a multiple protein complex essential for targeting exocytic vesicles to specific docking sites on the plasma membrane. Though best characterized in yeast, the component proteins and functions of exocyst complex have been demonstrated to be highly conserved in higher eukaryotes. At least eight components of the exocyst complex, including this protein, are found to interact with the actin cytoskeletal remodeling and vesicle transport machinery. The complex is also essential for the biogenesis of epithelial cell surface polarity.

Source: NCBI Gene 10640 — RefSeq curated summary.

At a glance

• GWAS associations: 4
• Clinical variants (ClinVar): 87 total
• Cancer dependency (DepMap): dependent in 48.8% of screened cell lines
• MANE Select transcript: NM_006544

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:10696
Approved symbol	EXOC5
Name	exocyst complex component 5
Location	14q22.3
Locus type	gene with protein product
Status	Approved
Aliases	SEC10, SEC10P
Ensembl gene	ENSG00000070367
Ensembl biotype	protein_coding
OMIM	604469
Entrez	10640

Gene structure

Transcript identifiers

Ensembl transcripts: 18 — 11 protein_coding, 4 retained_intron, 2 protein_coding_CDS_not_defined, 1 nonsense_mediated_decay

ENST00000340918, ENST00000554011, ENST00000554598, ENST00000554934, ENST00000555148, ENST00000555749, ENST00000556318, ENST00000556629, ENST00000556911, ENST00000621441, ENST00000854286, ENST00000854287, ENST00000854288, ENST00000854289, ENST00000854290, ENST00000854291, ENST00000970530, ENST00000970531

RefSeq mRNA: 1 — MANE Select: NM_006544 NM_006544

CCDS: CCDS45111

Canonical transcript exons

ENST00000621441 — 18 exons

Exon	Start	End
ENSE00002443973	57268622	57268905
ENSE00003488823	57233743	57233883
ENSE00003496703	57235711	57235820
ENSE00003503295	57222308	57222416
ENSE00003510016	57219322	57219442
ENSE00003526544	57209953	57210061
ENSE00003564306	57232667	57232749
ENSE00003565795	57231506	57231715
ENSE00003569373	57247618	57247712
ENSE00003574332	57233988	57234032
ENSE00003589753	57217982	57218068
ENSE00003616078	57246711	57246858
ENSE00003622495	57209567	57209782
ENSE00003636328	57244165	57244359
ENSE00003644036	57239595	57239659
ENSE00003660731	57229734	57229881
ENSE00003682033	57237338	57237366
ENSE00003723977	57200507	57208797

Expression profiles

Bgee: expression breadth ubiquitous, 255 present calls, max score 97.57.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 28.4784 / max 432.6813, expressed in 1818 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
143403	28.4784	1818

Top tissues by expression

256 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
cortical plate	UBERON:0005343	97.57	gold quality
ganglionic eminence	UBERON:0004023	97.47	gold quality
corpus callosum	UBERON:0002336	96.99	gold quality
ventricular zone	UBERON:0003053	96.52	gold quality
cardiac muscle of right atrium	UBERON:0003379	96.51	gold quality
left ventricle myocardium	UBERON:0006566	96.11	gold quality
inferior vagus X ganglion	UBERON:0005363	95.95	gold quality
calcaneal tendon	UBERON:0003701	95.84	gold quality
adrenal tissue	UBERON:0018303	95.53	gold quality
colonic epithelium	UBERON:0000397	95.43	gold quality
subthalamic nucleus	UBERON:0001906	95.32	gold quality
secondary oocyte	CL:0000655	95.28	gold quality
medulla oblongata	UBERON:0001896	95.25	gold quality
myocardium	UBERON:0002349	95.14	gold quality
superior vestibular nucleus	UBERON:0007227	95.07	gold quality
postcentral gyrus	UBERON:0002581	94.94	gold quality
islet of Langerhans	UBERON:0000006	94.63	gold quality
parietal lobe	UBERON:0001872	94.63	gold quality
cauda epididymis	UBERON:0004360	94.44	gold quality
caput epididymis	UBERON:0004358	94.33	gold quality
dorsal root ganglion	UBERON:0000044	94.31	gold quality
dorsal plus ventral thalamus	UBERON:0001897	94.23	gold quality
tibialis anterior	UBERON:0001385	94.19	gold quality
substantia nigra pars reticulata	UBERON:0001966	94.08	gold quality
adult organism	UBERON:0007023	94.00	gold quality
superficial temporal artery	UBERON:0001614	93.86	gold quality
kidney epithelium	UBERON:0004819	93.86	gold quality
trabecular bone tissue	UBERON:0002483	93.84	gold quality
substantia nigra pars compacta	UBERON:0001965	93.71	gold quality
deltoid	UBERON:0001476	93.70	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	5.86
E-MTAB-6075	no	573.06
E-GEOD-124858	no	379.57

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

353 targeting EXOC5, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-4262	100.00	73.26	3931
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-5692B	100.00	71.32	2622
HSA-MIR-5692C	100.00	71.32	2622
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-126-5P	100.00	72.71	3180
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-181A-5P	99.99	72.96	2995
HSA-MIR-181B-5P	99.99	72.97	2996
HSA-MIR-181C-5P	99.99	72.95	2996
HSA-MIR-181D-5P	99.99	73.04	2997
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-4500	99.99	72.72	2367
HSA-MIR-373-5P	99.98	75.36	4753
HSA-MIR-616-5P	99.98	75.58	4775
HSA-MIR-548P	99.98	72.25	3784
HSA-MIR-548N	99.98	71.94	4170
HSA-MIR-4482-3P	99.98	72.50	3147
HSA-MIR-19A-3P	99.98	75.33	2762
HSA-MIR-19B-3P	99.98	75.44	2754

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 48.8% of screened cell lines.

Literature-anchored findings (GeneRIF, showing 7)

• Data show that GTP-bound ARF6 interacts with Sec10, a subunit of the exocyst complex involved in docking of vesicles with the plasma membrane. (PMID:14662749)
• The exocyst protein Sec10 regulates primary ciliogenesis. (PMID:19297529)
• Exocyst Sec10 overexpression reduces damage to tubular epithelial barriers caused by hydrogen peroxide and speeds the recovery of normal epithelial barrier function after such an injury. (PMID:20053792)
• These data confirm that the exocyst is preferentially involved in basolateral protein translation and translocation, and may well act through the phosphorylation of Sec61beta. (PMID:23037926)
• Suggest that the exocyst sec10, acting through EGFR, endocytosis, and the MAPK pathway is a candidate therapeutic target for acute kidney injury. (PMID:25298525)
• show that EXOC5 mRNA almost completely rescues the ciliary phenotypes in exoc5-mutant zebrafish, unlike the EXOC5CTS-m mRNA, which could not efficiently rescue the phenotypes (PMID:30824539)
• The EXOC5 knockdown increases ARF6 levels and decreases EPS8L2 levels, and that EXOC5 overexpression increases EPS8L2. (PMID:31694916)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	exoc5	ENSDARG00000060323
mus_musculus	Exoc5	ENSMUSG00000061244
rattus_norvegicus	Exoc5	ENSRNOG00000013804
drosophila_melanogaster	Sec10	FBGN0266673
caenorhabditis_elegans		WBGENE00016376

Protein

Protein identifiers

Exocyst complex component 5 — O00471 (reviewed: O00471)

Alternative names: Exocyst complex component Sec10

All UniProt accessions (4): O00471, F8W9B8, G3V377, G3V4Z7

UniProt curated annotations — full annotation on UniProt →

Function. Component of the exocyst complex involved in the docking of exocytic vesicles with fusion sites on the plasma membrane.

Subunit / interactions. The exocyst complex is composed of EXOC1, EXOC2, EXOC3, EXOC4, EXOC5, EXOC6, EXOC7 and EXOC8. Interacts with EXOC3L1.

Subcellular location. Cytoplasm. Midbody.

Tissue specificity. Ubiquitous.

Similarity. Belongs to the SEC10 family.

RefSeq proteins (1): NP_006535* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR009976	Sec10-like	Family
IPR048625	Sec10_N	Domain
IPR048627	Sec10_HB	Domain

Pfam: PF07393, PF20667

UniProt features (10 total): modified residue 5, initiator methionine 1, chain 1, coiled-coil region 1, sequence variant 1, sequence conflict 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-O00471-F1	87.04	0.56

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (5): 2, 122, 395, 405, 412

Function

Pathways and Gene Ontology

Reactome pathways

3 pathways

ID	Pathway
R-HSA-1445148	Translocation of SLC2A4 (GLUT4) to the plasma membrane
R-HSA-264876	Insulin processing
R-HSA-5620916	VxPx cargo-targeting to cilium

MSigDB gene sets: 261 (showing top): GOBP_MITOTIC_CYTOKINESIS, GOBP_MORPHOGENESIS_OF_AN_EPITHELIUM, RODRIGUES_THYROID_CARCINOMA_ANAPLASTIC_UP, GOBP_EPITHELIUM_DEVELOPMENT, MYOGENIN_Q6, RODRIGUES_THYROID_CARCINOMA_POORLY_DIFFERENTIATED_UP, GOBP_VESICLE_LOCALIZATION, AMIT_EGF_RESPONSE_60_HELA, GCANCTGNY_MYOD_Q6, GCM_ZNF198, IVANOVA_HEMATOPOIESIS_LATE_PROGENITOR, GOBP_VESICLE_TARGETING, GCM_PPM1D, GOBP_VESICLE_MEDIATED_TRANSPORT, REACTOME_MEMBRANE_TRAFFICKING

GO Biological Process (14): mitotic cytokinesis (GO:0000281), establishment of planar polarity (GO:0001736), exocytosis (GO:0006887), post-Golgi vesicle-mediated transport (GO:0006892), Golgi to plasma membrane transport (GO:0006893), obsolete vesicle docking involved in exocytosis (GO:0006904), protein transport (GO:0015031), homeostasis of number of cells within a tissue (GO:0048873), protein localization to plasma membrane (GO:0072659), membrane fission (GO:0090148), obsolete vesicle tethering involved in exocytosis (GO:0090522), epithelial cell apoptotic process (GO:1904019), non-motile cilium assembly (GO:1905515), morphogenesis of a polarized epithelium (GO:0001738)

GO Molecular Function (2): small GTPase binding (GO:0031267), protein binding (GO:0005515)

GO Cellular Component (4): exocyst (GO:0000145), cytoplasm (GO:0005737), cytosol (GO:0005829), midbody (GO:0030496)

Reactome top-level categories

Rollup of top-3 pathways:

Category	Pathways
Membrane Trafficking	1
Peptide hormone metabolism	1
Cargo trafficking to the periciliary membrane	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
mitotic cell cycle	1
cytoskeleton-dependent cytokinesis	1
mitotic cell cycle process	1
morphogenesis of a polarized epithelium	1
establishment of tissue polarity	1
vesicle-mediated transport	1
secretion by cell	1
vesicle fusion to plasma membrane	1
Golgi vesicle transport	1
post-Golgi vesicle-mediated transport	1
vesicle-mediated transport to the plasma membrane	1
transport	1
intracellular protein localization	1
establishment of protein localization	1
tissue homeostasis	1
homeostasis of number of cells	1
protein localization to membrane	1
protein localization to cell periphery	1
membrane organization	1
apoptotic process	1
cilium assembly	1
morphogenesis of an epithelium	1
GTPase binding	1
binding	1
cell cortex	1
vesicle tethering complex	1
intracellular anatomical structure	1
cytoplasm	1

Protein interactions and networks

STRING

1854 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
EXOC5	EXOC4	Q96A65	999
EXOC5	EXOC6	Q8TAG9	999
EXOC5	EXOC1	Q9NV70	999
EXOC5	EXOC3	O60645	999
EXOC5	EXOC2	Q96KP1	998
EXOC5	EXOC7	Q9UPT5	998
EXOC5	EXOC8	Q8IYI6	998
EXOC5	ARF6	P26438	963
EXOC5	CTNNB1	P35222	851
EXOC5	CDC42	P21181	803
EXOC5	EXOC6B	Q9Y2D4	800
EXOC5	PKD2	Q13563	792
EXOC5	IFT20	Q8IY31	752
EXOC5	IFT88	Q13099	710
EXOC5	VPS53	Q5VIR6	669

IntAct

328 interactions, top by confidence:

A	B	Type	Score
EXOC6	EXOC5	psi-mi:“MI:0914”(association)	0.840
EXOC5	EXOC6	psi-mi:“MI:0915”(physical association)	0.840
EXOC6B	EXOC5	psi-mi:“MI:0914”(association)	0.790
EXOC3	EXOC5	psi-mi:“MI:0914”(association)	0.790
EXOC5	EXOC6B	psi-mi:“MI:0915”(physical association)	0.790
EXOC1	EXOC5	psi-mi:“MI:0914”(association)	0.730
EXOC8	EXOC5	psi-mi:“MI:0914”(association)	0.730
DEUP1	EXOC5	psi-mi:“MI:0915”(physical association)	0.720
EXOC5	RAB4A	psi-mi:“MI:0915”(physical association)	0.720
RAB4B	EXOC5	psi-mi:“MI:0915”(physical association)	0.720
RAB14	EXOC5	psi-mi:“MI:0915”(physical association)	0.720
EXOC5	PTK6	psi-mi:“MI:0915”(physical association)	0.720
MAGEA6	EXOC5	psi-mi:“MI:0915”(physical association)	0.720
EXOC5	DEUP1	psi-mi:“MI:0915”(physical association)	0.720
RAB4A	EXOC5	psi-mi:“MI:0915”(physical association)	0.720
EXOC5	RAB14	psi-mi:“MI:0915”(physical association)	0.720
PTK6	EXOC5	psi-mi:“MI:0915”(physical association)	0.720

BioGRID (211): EXOC5 (Two-hybrid), EXOC5 (Two-hybrid), EXOC5 (Two-hybrid), EXOC5 (Two-hybrid), EXOC5 (Two-hybrid), EXOC5 (Two-hybrid), EXOC5 (Two-hybrid), TXNL4A (Two-hybrid), C9orf9 (Two-hybrid), EDRF1 (Two-hybrid), PYCARD (Two-hybrid), TNPO2 (Two-hybrid), RAB14 (Two-hybrid), RAB4B (Two-hybrid), KXD1 (Two-hybrid)

ESM2 similar proteins: A3KQV2, A4IIL4, O00471, O54921, P48553, P62944, P63009, P63010, P79020, P97878, Q00004, Q0IIZ5, Q1L8F9, Q29RF7, Q3SYS9, Q3TLI0, Q3TPX4, Q498H0, Q4G074, Q4QR29, Q4V8K5, Q4VA53, Q5F3K0, Q5KU05, Q5R6J0, Q5RDD7, Q5VW32, Q5VYK3, Q62018, Q6DDM4, Q6DEU9, Q6IR80, Q6P1I3, Q6PD62, Q6PDI5, Q6TRW4, Q6ZPU9, Q8BMA6, Q8K2Q7, Q8WUM4

Diamond homologs: O00471, P97878, Q18406, Q3TPX4, Q9XTM1

SIGNOR signaling

2 interactions.

A	Effect	B	Mechanism
EXOC5	“form complex”	“Exocyst_EXOC6B variant”	binding
EXOC5	“form complex”	“Exocyst_EXOC6 variant”	binding

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 82 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
VxPx cargo-targeting to cilium	8	75.5×	1e-11
Insulin processing	7	58.1×	2e-09
Translocation of SLC2A4 (GLUT4) to the plasma membrane	10	28.1×	2e-10

GO biological processes:

GO term	Partners	Fold	FDR
obsolete vesicle docking involved in exocytosis	9	83.1×	2e-13
membrane fission	9	50.7×	2e-11
Golgi to plasma membrane transport	6	46.2×	4e-07
mitotic cytokinesis	8	28.4×	5e-08
exocytosis	11	22.9×	3e-10
regulation of macroautophagy	5	20.2×	4e-04
vesicle-mediated transport	6	7.9×	8e-03
intracellular protein transport	8	7.1×	1e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

87 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	65
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

2710 predictions. Top by Δscore:

Variant	Effect	Δscore
14:57208612:G:C	donor_gain	1.0000
14:57209947:ACT:A	donor_loss	1.0000
14:57209948:CTC:C	donor_loss	1.0000
14:57209950:C:CC	donor_loss	1.0000
14:57209951:A:AC	donor_gain	1.0000
14:57209951:A:T	donor_loss	1.0000
14:57209952:C:CA	donor_gain	1.0000
14:57209952:CA:C	donor_gain	1.0000
14:57209952:CAT:C	donor_gain	1.0000
14:57209952:CATT:C	donor_gain	1.0000
14:57209952:CATTA:C	donor_gain	1.0000
14:57210058:TGTC:T	acceptor_gain	1.0000
14:57210062:CTAGA:C	acceptor_loss	1.0000
14:57217974:CAA:C	donor_gain	1.0000
14:57218066:GAGC:G	acceptor_loss	1.0000
14:57218067:AGCTA:A	acceptor_loss	1.0000
14:57218068:GC:G	acceptor_loss	1.0000
14:57218069:C:CC	acceptor_gain	1.0000
14:57218069:C:CG	acceptor_loss	1.0000
14:57218072:T:C	acceptor_gain	1.0000
14:57218072:T:TC	acceptor_gain	1.0000
14:57218074:G:C	acceptor_gain	1.0000
14:57218074:G:GC	acceptor_gain	1.0000
14:57218076:A:AC	acceptor_gain	1.0000
14:57218076:A:C	acceptor_gain	1.0000
14:57218078:A:C	acceptor_gain	1.0000
14:57218079:T:TC	acceptor_gain	1.0000
14:57218080:T:C	acceptor_gain	1.0000
14:57218080:T:TC	acceptor_gain	1.0000
14:57219317:CTAA:C	donor_loss	1.0000

AlphaMissense

4746 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
14:57217991:C:T	G535D	1.000
14:57235793:A:G	L196P	1.000
14:57237363:A:C	F178L	1.000
14:57237363:A:T	F178L	1.000
14:57237365:A:G	F178L	1.000
14:57239616:G:T	A170D	1.000
14:57239617:C:G	A170P	1.000
14:57239628:A:G	L166S	1.000
14:57244242:C:G	A130P	1.000
14:57244251:C:G	A127P	1.000
14:57244253:C:G	R126P	1.000
14:57244258:T:A	R124S	1.000
14:57244258:T:G	R124S	1.000
14:57244280:A:G	L117S	1.000
14:57244283:T:G	Q116P	1.000
14:57244289:C:A	G114V	1.000
14:57244289:C:T	G114E	1.000
14:57244290:C:G	G114R	1.000
14:57244290:C:T	G114R	1.000
14:57244292:A:G	L113P	1.000
14:57244310:G:T	A107E	1.000
14:57244311:C:G	A107P	1.000
14:57244334:A:G	L99P	1.000
14:57208653:G:T	R695S	0.999
14:57208748:A:G	L663P	0.999
14:57209652:A:G	L618P	0.999
14:57209686:C:G	G607R	0.999
14:57209686:C:T	G607R	0.999
14:57209777:A:C	C576W	0.999
14:57217992:C:G	G535R	0.999

dbSNP variants (sampled 300 via entrez): RS1000025808 (14:57254849 T>C), RS1000064446 (14:57261853 C>G), RS1000090114 (14:57213354 C>T), RS1000214942 (14:57236172 G>T), RS1000252713 (14:57264409 A>G), RS1000255178 (14:57224115 A>G), RS1000360154 (14:57211683 G>A), RS1000407192 (14:57218974 A>C,G), RS1000465581 (14:57217871 T>C), RS1000491889 (14:57242191 G>A,C), RS1000543838 (14:57246951 G>C), RS1000554217 (14:57230095 A>G), RS1000577587 (14:57265735 A>C), RS1000601105 (14:57224402 G>A), RS1000613824 (14:57253529 T>C)

Disease associations

OMIM: gene MIM:604469 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

4 associations (top):

Study	Trait	p-value
GCST002065_9	Alcohol consumption	9.000000e-06
GCST006277_1	Response to ranibizumab in age-related macular degeneration (exudative)	7.000000e-07
GCST007576_118	Chronotype	4.000000e-11
GCST011743_3	HDL cholesterol levels in HIV infection	6.000000e-06

EFO canonical traits (4, from GWAS)

EFO ID	Trait name
EFO:0004329	alcohol drinking
EFO:0008348	response to ranibizumab
EFO:0008328	chronotype measurement
EFO:0004612	high density lipoprotein cholesterol measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

45 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, decreases expression, decreases methylation	4
trichostatin A	affects cotreatment, decreases expression	3
Endosulfan	increases expression, decreases expression	2
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	decreases expression	2
Particulate Matter	decreases expression, increases abundance, increases expression	2
aristolochic acid I	decreases expression	1
FR900359	increases phosphorylation	1
bisphenol F	increases expression	1
dicrotophos	decreases expression	1
methylmercuric chloride	decreases expression	1
triphenyl phosphate	affects expression	1
bisphenol A	decreases methylation	1
cobaltous chloride	affects cotreatment, increases expression	1
tetrabromobisphenol A	decreases expression	1
lead chloride	affects cotreatment, increases expression	1
4-aminophenylarsenoxide	affects binding, decreases reaction	1
1-nitropyrene	increases expression	1
cadmium sulfate	affects cotreatment, increases expression	1
CGP 52608	increases reaction, affects binding	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	decreases expression, affects cotreatment	1
bisphenol B	increases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
jinfukang	decreases expression	1
Resveratrol	affects cotreatment, increases expression	1
Zoledronic Acid	increases expression	1
Arsenic Trioxide	affects binding, decreases reaction	1
Acetaminophen	decreases expression	1
Air Pollutants	decreases expression, increases abundance	1
Atrazine	decreases expression	1
Vehicle Emissions	increases abundance, increases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.